Patents by Inventor Margaret Galvin

Margaret Galvin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Genotyping the human UDP-glucuronosyl transferase 1 (UGT1) gene
    Publication number: 20030157517
    Abstract: Genetic polymorphisms are identified in the human UGT1 gene that alter UGT1-dependent drug metabolism. Nucleic acids comprising the polymorphic sequences are used to screen patients for altered metabolism for UGT1 substrates, potential drug-drug interactions, and adverse/side effects, as well as diseases that result from environmental or occupational exposure to toxins. The nucleic acids are used to establish animal, cell and in vitro models for drug metabolism.
    Type: Application
    Filed: September 18, 2002
    Publication date: August 21, 2003
    Applicant: DNA Sciences Laboratories, Inc.
    Inventors: Laura Penny, Margaret Galvin
  • Genotyping the human UDP-glucuronosyltransferase 2B7 (UGT2B7) gene
    Patent number: 6586175
    Abstract: Genetic polymorphisms are identified in the human UGT2B4, UGT2B7 and UGT2B15 genes that alter UGT2B activity. Nucleic acids comprising the polymorphic sequences are used to screen patients for altered metabolism for UGT2B substrates, potential drug-drug interactions, and adverse/side effects, as well as diseases that result from environmental or occupational exposure to toxins. The nucleic acids are used to establish animal, cell and in vitro models for drug metabolism.
    Type: Grant
    Filed: July 20, 1999
    Date of Patent: July 1, 2003
    Assignee: DNA Sciences Laboratories, Inc.
    Inventors: Margaret Galvin, Andrew Miller, Laura Penny, Michael Riedy
  • Genotyping human UDP-Glucuronsyltransferase 2B15 (UGT2B15) genes
    Publication number: 20030077629
    Abstract: Genetic polymorphisms are identified in the human UGT2B4, UGT2B7 and UGT2B15 genes that alter UGT2B activity. Nucleic acids comprising the polymorphic sequences are used to screen patients for altered metabolism for UGT2B substrates, potential drug-drug interactions, and adverse/side effects, as well as diseases that result from environmental or occupational exposure to toxins. The nucleic acids are used to establish animal, cell and in vitro models for drug metabolism.
    Type: Application
    Filed: July 24, 2002
    Publication date: April 24, 2003
    Applicant: DNA Sciences, Inc.
    Inventors: Margaret Galvin, Andrew Miller, Laura Penny, Michael Riedy
  • Genotyping the human UDP-glucuronosyltransferase 1 (UGT1) gene
    Patent number: 6479236
    Abstract: Genetic polymorphisms are identified in the human UGT1 gene that alter UGT1-dependent drug metabolism. Nucleic acids comprising the polymorphic sequences are used to screen patients for altered metabolism for UGT1 substrates, potential drug-drug interactions, and adverse/side effects, as well as diseases that result from environmental or occupational exposure to toxins. The nucleic acids are used to establish animal, cell and in vitro models for drug metabolism.
    Type: Grant
    Filed: May 5, 1999
    Date of Patent: November 12, 2002
    Assignee: DNA Sciences Laboratories, Inc.
    Inventors: Laura Penny, Margaret Galvin
  • GENOTYPING THE HUMAN UDP-GLUCURONOSYLTRANSFERASE 1 (UGT1) GENE
    Publication number: 20020061518
    Abstract: Genetic polymorphisms are identified in the human UGT1 gene that alter UGT1-dependent drug metabolism. Nucleic acids comprising the polymorphic sequences are used to screen patients for altered metabolism for UGT1 substrates, potential drug-drug interactions, and adverse/side effects, as well as diseases that result from environmental or occupational exposure to toxins. The nucleic acids are used to establish animal, cell and in vitro models for drug metabolism.
    Type: Application
    Filed: May 5, 1999
    Publication date: May 23, 2002
    Inventors: LAURA PENNY, MARGARET GALVIN
  • Asthma related genes
    Patent number: 6087485
    Abstract: A genetic locus associated with asthma is identified. The genes within the locus, ASTH1I and ASTH1J, and the regulatory sequences of the locus are characterized. The genes are used to produce the encoded proteins; in screening for compositions that modulate the expression or function of ASTH1 proteins; and in studying associated physiological pathways. The DNA is further used as a diagnostic for genetic predisposition to asthma.
    Type: Grant
    Filed: January 21, 1998
    Date of Patent: July 11, 2000
    Assignee: AxyS Pharmaceuticals, Inc.
    Inventors: Angela R. Brooks-Wilson, Alan Buckler, Lon Cardon, Alisoun H. Carey, Margaret Galvin, Andrew Miller, Michael North